Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas Blood, Mar 2013; 121: 2563 - 2566.
[anti-HA]
Regulation of the PI3-K/Akt Survival Pathway in the Rat Endometrium Biol Reprod, Mar 2013; 88: 79.
[Akt3]
RNA elements directing in vivo assembly of the 7SK/MePCE/Larp7 transcriptional regulatory snRNP Nucleic Acids Res., Mar 2013; 10.1093/nar/gkt159.
[LA]
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements Haematologica, Mar 2013; 98: 404 - 408.
[JAK2]
A synthetic peptide corresponding to residues in human Vimentin was used as an immunogen.
Buffer
Store at -20C. Buffer: 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA. Stable for 12 months from date of receipt.
Vimentin is the most common member of the intermediate filament (IF) family and one of the main components in the cytoskeleton structure. It is expressed during cell development and differentiation in a variety of mesenchymally and mesodermally derived cells (1). Vimentin is essential in cell integrity and cytoskeletal stability. The reorganization of vimentin, similar to all IF proteins, occurs during different stages of the cell cycle and cell signaling by a site-specific phosphorylation (serine and threonine residues) (2). Vimentin interacts with other proteins such as uridine phosphorylase and desmoplakin (3, 4). It is highly expressed in fibroblasts and many hormone-independent mammary carcinoma cell lines (5).
Related Pathway
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
